ArQule's lead molecule moves into Phase III for lung cancer
This article was originally published in Scrip
Daiichi Sankyo and ArQule have recruited the first patient into an international Phase III clinical programme for ArQule's lead development project ARQ 197, for the treatment of locally advanced/metastatic non-small cell lung cancer (NSCLC).
You may also be interested in...
Given its ever-growing role as a critical component of the global biopharma industry, you can’t afford not to be up to speed on Asia. This biweekly selection of insights from our experienced on-the-ground team will help.
Plus deals involving LegoChem/Pyxix, Biohaven/Sosei Heptares, Kyowa Kirin/Helsinn, Dr. Reddy’s/Glenmark, Eisai/Wren, KoBioLabs/Kolmar Korea, Y-Biologics/Pierre Fabre, Generex/Chinese consortium.
Join us for a brief audio tour around the past week's major global biopharma industry developments, in this podcast version of Scrip's Five Must-Know Things.